Searched for
ALKEM LABORATORIES ACQUISITION
Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...- Alkem Labs unit to buy up to 55% of Occlutech for $118 millionAlkem Laboratories is entering the advanced cardiovascular devices market. Its medical devices unit will acquire a significant stake in Swi...
- TIMF Holdings, 360 ONE Funds invest Rs 140 cr in Rubicon Research ahead of IPORubicon Research secured Rs 140 crore from TIMF Holdings and 360 ONE funds before its IPO. General Atlantic Singapore RR Pte transferred sh...
- Alkem Labs acquires two companies specialising in skin care, medtech to bolster domestic businessAlkem Laboratories has announced two strategic acquisitions totaling Rs 287 crores to strengthen its domestic market presence. The company ...
- Alkem joins $3 bn race for JB Chem as Torrent pauses talksAlkem Laboratories, India's fifth-largest branded pharmaceutical company, is vying for JB Chemicals and Pharmaceuticals as KKR looks to sel...
- Stocks in news: Zomato, Paytm, Zen Technologies, Coal India, IREDA, Alkem LabsMarkets increased on Wednesday. Zomato approved a deal with Paytm. Coal India pursued lithium acquisitions. Zen Technologies launched a QIP...
- Akums Drugs files draft IPO papers with Sebi; eyes Rs 680 cr via fresh issueThe company is looking to raise Rs 136 crore through a pre-IPO placement. If such placement is undertaken, then fresh issue size will be re...
- ETIG IPO Analysis: Entero Healthcare may Offer Better Value Post ListingIncorporated in 2018 and founded by a former chief executive of Alkem Laboratories, Mumbai-based Entero Healthcare Solutions has grown to b...
- Alkem Labs to grow chronic therapies, biosimilars to drive future growth: MDAlkem Laboratories, a top-seller of antibiotics, is focusing on the chronic therapy segments and is investing heavily in biosimilars and co...
- Alkem looks for partnerships, in-licensing deals to bolster presence in US market"The company would also strategically look at in-licensing opportunities, alliances and partnerships to enhance its capabilities and produc...
- Alkem looks for partnerships, in-licensing deals to bolster presence in US market"The company would also strategically look at in-licensing opportunities, alliances and partnerships to enhance its capabilities and produc...
- Medlife revenue up 165% to Rs 363 cr, losses surge tooIn August, Medlife appointed former Myntra CEO Ananth Narayanan as CEO and cofounder, with a mandate to head day-to-day operations, raise f...
- Myntra ex-chief Narayanan may check into Medlife as CEOAnanth Narayanan has also invested personal capital in the e-pharma company.
- Medlife acquires Myra to take ePharma service to 22 citiesBengaluru startup’s acquisition indicates early signs of consolidation in the sector
- Alkem Labs to tap domestic, international markets for growthIn the domestic market, the company plans to consolidate presence in the segments it is in and is aiming to build base in the emerging ther...
- Alkem Labs May Inspire Other Pharma Cos to Take IPO PathWith many unlisted cos in sector, chances of them tapping mkt looks high: Nomura Fin's Oza.
- Alkem Laboratories hits IPO mart on December 8; three factors to look out forDomestic pharma major Alkem Laboratories is all set to hit the primary market on December 8, seeking to raise Rs 1,355 crore.
- Alkem Laboratories fixes IPO price band at Rs 1,020-1,050Pharma firm, Alkem Laboratories has fixed the price band between Rs 1,020 and Rs 1,050 for its IPO, which will hit the capital markets on D...
- Pharmaceutical company Alkem Laboratories eyeing big-bang IPO in FY-1580% of the company's revenues currently come from domestic operations and now it's main focus is on the US market.
- How does the Sun Pharma-Ranbaxy deal change the game for the other players in the Indian pharma market?The combined market share of Sun Pharma (5.4% at present) and Ranbaxy (3.8%) will be 9.2%; much higher than that of the current No. 1 playe...
Load More
